The historical data trend for Q-linea AB's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:QLINES vs ABT, SYK, MDT: Buyback Yield % Comparison
For the Medical Devices subindustry, Q-linea AB's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-linea AB Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-linea AB's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Q-linea AB's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-linea AB (CHIX:QLINES) has a Buyback Yield % of -116.61 as of Jul. 05, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Q-linea AB and its competitors. According to the industry distribution chart, Q-linea AB ranks #330 out of 347 companies in the Medical Devices & Instruments industry, placing it in the top 95.1%.
Is Q-linea AB's Buyback Yield % too high?
Q-linea AB's current Buyback Yield % is -116.61. Based on the distribution chart, Q-linea AB ranks #330 out of 347 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Q-linea AB has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's Buyback Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-linea AB ranks #330 out of 347 companies for Buyback Yield %. This places Q-linea AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Q-linea AB and its competitors. Q-linea AB's current Buyback Yield % is -116.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Q-linea AB (CHIX:QLINES) has a current Buyback Yield % of -116.61. The stock's GF Value™ is kr1,981.69, compared to a current price of kr1,610.00 — trading 18.8% below its estimated fair value. The current Buyback Yield % is -116.61. Q-linea AB's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Q-linea AB (CHIX:QLINES), the current Buyback Yield % is -116.61 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Q-linea AB (CHIX:QLINES) Overvalued in 2026?
Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued.
The current stock price of kr1,610.00 is trading 18.8% below its estimated GF Value™ of kr1,981.69.
Key valuation signals for CHIX:QLINES:
Buyback Yield %: -116.61
GF Value™: kr1,981.69 vs. price of kr1,610.00 (18.8% below fair value)
No single metric tells the full story. See the CHIX:QLINES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
68GF Score
Get the complete analysis for CHIX:QLINES
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:QLINES has been successfully added to your 
